US 2026/0092279 A1 · DOUBLE-STRANDED RNAI AGENTS AND COMPOSITIONS FOR REDUCING EXPRESSION OF ANGIOPOIETIN-LIKE 3 (ANGPTL3) AND METHODS OF USE THEREOF

Abstract

There are disclosed certain double-stranded RNA (dsRNA) or siRNA agents for inhibition of angiopoietin-like 3 gene expression, compositions that include angiopoietin-like 3 agents and methods of use thereof. The double-stranded RNA (dsRNA) or siRNA agents are particularly useful in the treatment or prophylaxis of cardiovascular disease and metabolic conditions as well as in the treatment of heart failure and chronic kidney disease.

Claims9

Dependent claims

An angiopoietin-like 3 (ANGPTL3) siRNA agent comprising (i) a sense strand having the sequence:

[M]-mC mU mA mC mA mU fA fU fA mA mA mC mU mA mC mA mA (ps) mG (ps) mU (SEQ ID NO:
11),
and (ii) a antisense strand having the sequence:
mA (ps) fC (ps) mU fU mG fU mA fG mU fU mU fA mU fA mU fG mU (ps) fA (ps) mG (SEQ ID NO:
5),
where [M] is a triantennary ligand moiety linked to the 5′ end of the sense strand and has the structure:
or a pharmaceutically acceptable salt thereof.

4 more elements

Dependencies are inferred from the claim text.

Facts

Application

19/344,040Filed 29 Sep 2025

Priority

EP 24156795.79 Feb 2024

Published

2 Apr 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

C12N 15/1136
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming…: against…
A61P 3/06
Drugs for disorders of the metabolism: antihyperlipidemics
C12N 2310/14
Type of nucleic acid: interfering nucleic acids [NA]
C12N 2310/315
Of the backbone: phosphorothioates

Double-stranded rnai agents and compositions for reducing expression of angiopoietin-like 3 (angptl3) and methods of use thereof

Life of this patent

Double-stranded rnai agents and compositions for reducing expression of angiopoietin-like 3 (angptl3) and methods of use thereof

Life of this patent

Abstract

Claims9